参考文献/References:
[1] SEER Cancer Statistics Fact sheets:Thyroid Cancer.National Cancer Institute[DB/OL].Bethesda (MD):National Cancer Insti-tube[2015-01-06].http://seer.cancer.gov/statfacts/html/thyro.html.
[2] Eustatia-Rutten CF,Smit JW,Romijn JA,et al.Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma,a structured meta-analysis[J].Clin Endocrinol(Oxf),2004,61(1):61-74.
[3] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty GM,et al.Revised American thyroid association manage-ment guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19(11):1167-1214.
[4] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志,2012,28(10):779-797.
[5] Lima N,Cavanere H,Tomimori E,et al.Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for dif-ferentiated thyroid cancer[J].J Endocrinol Invest,2002,25(2):110-115.
[6] Mazzaferri EL,Robbins RJ,Spencer CA,et al.A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma[J].J Clin Endocrinol Metab,2003,88(4): 1433-1441.
[7] Bachelot A,Leboulleux S,Baudin E,et al.Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment[J].Clin Endocrinol (Oxf),2005,62(3): 376-379.
[8] Baloch Z,Carayon P,Conte-Devolx B,et al.Laboratory medicine practice guidelines.Laboratory support for the diagnosis and moni-toring of thyroid disease[J].Thyroid,2003,13(1):3-126.
[9] Valle LA,Gorodeski Baskin RL,Porter K,et al.In thyroidectomized patients with thyroid cancer,a serum thyrotropin of 30μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin[J].Thyroid,2013,23(2):185-193.
[10] Spencer CA,Takeuchi M,Kazarosyan M,et al.Serum thyroglobulin autoantibodies: Prevalence,influence on serum thyroglobulin measurement,and prognostic significance in patients with differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,1998,83(4):1121-1127.
[11] Rahmoun MN,Bendahmane I.Anti-thyroglobulin antibodies in differentiated thyroid carcinoma patients: study of the clinical and biological parameters[J].Ann Endocrinol (Paris),2014,75(1):15-18.
[12] Durante C,Tognini S,Montesano T,et al.Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer andcirculating anti-thyroglobulin autoantibodies[J].Thyroid,2014,24(7):1139-1145.
[13] Tsushima Y,Miyauchi A,Ito Y,et al.Prognostic significance of changes in serum thyroglobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients[J].Endocr J,2013,60(7):871-876.
[14] 戴庆靖,匡安仁.甲状腺球蛋白抗体对电化学发光免疫分析法测定甲状腺球蛋白的影响[J].生物医学工程学杂志,2011,28(4):780-783.
[15] Phan HT,Jager PL,van der Wal JE,et al.The follow-up of patients with differentiated thyroid cancer and undetectable thymglobulin (Tg) and Tg antibodies during ablation[J].Eur J Endocrinol,2008.158(1):77-83.
[16] Salvatori M,Raffaelli M,Castaldi P,et al.Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma[J].Eur J Surg Oncol,2007,33(5):648-654.
[17] Toubeau M,Touzery C,Arveux P,et al.Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after I-131 ablation therapy in patients with differentiated thyroid cancer[J].J Nucl Med,2004,45(6):988-994.
[18] Kim TY,Kim WB,Kim ES,et al.Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,2005,90(3):1440-1445.
[19] 邱忠领,罗全勇.甲状腺球蛋白与分化型甲状腺癌[J].国际放射医学核医学杂志,2009,33(2):89-92.
[20] Piccardo A,Arecco F,Puntoni M,et al.Focus on high-risk DTC patients:high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival[J].Clin Nucl Med,2013,38(1):18-24.
[21] Rosario PW,Xavier AC,Calsolari MR.Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence[J].Thyroid,2011,21(1):49-53.
[22] Kim H,Kim SJ,Kim IJ,et al.Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer[J].Nucl Med Mol Imaging,2013,47(4):268-272.
[23] González C,Aulinas A,Colom C,et al.Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differen-tiated thyroid carcinoma[J].Clin Endocrinol (Oxf),2014,80(2):301-306.
[24] Pacini F,Molinaro E,Lippi F,et al.Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,2001,86(12):5686-5690.
[25] Tourniaire J,Bernard MH,Ayzac L,et al.Serum thyroglobulin assay after total unilateral thyroid lobectomy for differentiated thyroid carcer[J].Presse Me d,1990,19(28):1309-1312.
[26] Webb RC,Howard RS,Stojadinovic A,et al.The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer:a meta-analysis involving 3947 patients[J].J Clin Endocrinol Metab,2012,97(8):2754-2763.
[27] Giovanella L,Ceriani L,Chelfo A,et al.Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma[J].Clin Chem Lab Med,2005,43(8):843-847.
[28] Heemstra KA,Liu YY,Stokkel M,et al.Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma[J].Clin Endocrinol (Oxf),2007,66(1):58-64.
[29] Hall FT,Beasley NJ,Eski SJ,et al.Predictive value of serum thyroglobulin after surgery for thyroid carcinoma[Jj.Laryngoscope,2003,113(1):77-81.
[30] Kim MH,Ko SH,Bae JS,et al.Combination of initial stimulation thyroglobulins and staging system by revised A T A guidelines can elaborately discriminate prognosis of patients with differentiated thyroid carcinoma after high-dose remnant ablation[J].Clin Nucl Med,2012,37(11):1069-1074.
[31] Clappuccini R,Hardouin J,Heutte N,et al.Stimulated thyroglobulin level at ablation in differentiated thyroid cancer:the impact of treatment preparation modalities and tumor burden[J].Eur J Endocrinol,2014,171(2):247-252.
[32] Makarewicz J,Adamczewski Z,Knapska-Kucharska M.Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery[J].Exp Clin Endocrinol Diabetes,2006,114(9):485-489.
[33] de Rosario PW,Guimaraes VC,Maia FF,et al.Thyroglobulin be-fore ablation and correlation with posttreatment scanning[J].Laryn-goscope,2005,115(2):264-267.
[34] Lin Y,Li T,Liang J,et al.Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer[J].Clin Nucl Med,2011,36(12):1102-1105.
[35] 李田军,林岩松,梁军,等.131I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值[J].中华核医学与分子影像杂志,2012,32(3):189-191.
[36] Tamilia M,Al-Kahtani N,Rochon L,et al.Serum thyroglobulin predicts thyroid remnant ablation failure with 30mCi iodine-131 treatment in patients with papillary thyroid carcinoma[J].Nucl Med Commun,2011,32(3):212-220.
[37] Bernier MO,Morel O,Rodien P,et al.Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer[J].Eur J Nucl Med Mol Imaging,2005,32(12):1418-1421.
[38] Lee JI,Chung YJ,Cho BY,et al.Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma[J].Surgery,2013,153(6):828-835.
[39] Zubair Hussain S,Zaman MU,Malik S,et al.Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I131 Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy[J/OL].J Thyroid Res,2014,2014[2015-01-06].http://dx.doi.org/10.1155/2014/610273.[published online ahead of print Apr 9,2014].
[40] Lee CW,Roh JL,Gong G,et al.Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck[J].Ann Surg Oncol,2015,22(1):117-124.
[41] Lin JD,Huang MJ,Hsu BR,et al.Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas[J].J Surg Oncol,2002,80(1):45-51.
[42] Huang IC,Chou FF,Liu RT,et al.Long-term outcomes of distant metastasis from differentiated thyroid carcinoma[J].Clin Endocrinol(Oxf),2012,76(3):439-447.
[43] Kim HJ,Lee JI,Kim NK,et al.Prognostic implications of radioiodine avidity and serum thyroglobulin in differentiated thyroid carcinoma with distant metastasis[J].World J Surg,2013,37(12):2845-2852.
[44] Vaisman A,Orlov S,Yip J,et al.Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma[J].Head Neck,2010,32(6):689-698.
[45] Rosario PW,Mineiro Filho AF,Prates BS,et al.Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive Iodine ablation[J].Thyroid,2012,22(11):1140-1143.
[46] Ibrahimpasic T,Nixon I J,Palmer F L,et al.Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer is there a need for ra-dioactive iodine therapy?[J].Surgery,2012,152(6):1096-1105.
[47] National Comprehensive Cancer Network.NCCN Guidelines Ver-sion 1.2013 thyroid carcinoma[EB/OL].[2015-01-06].http://www.nccn.org/professionals/physician-gls/pdf/thyroid.pdf.
[48] Hackshaw A,Harmer C,Mallick U,et al.131I activity for remnant ablation in patients with differentiated thyroid cancer:a systemat-ic review[J].J Clin Endocrinol Metab,2007,92(1):28-38.
[49] M?enp?? HO,Heikkonen J,Vaalavirta L,et al.Low vs.high ra-dioiodine activity to ablate the thyroid after thyroidectomy for can-cer:a randomized study[J/OL].PLoS One,2008,3(4):e1885[2015-01-06].http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001885.
[50] Mallick U,Harmer C,Yap B,et al.Ablation with low-dose radioio-dine and thyrotropin alfa in thyroid cancer[J].N Engl J Med,2012,366(18):1674-1685.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[11]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[12]林军,缪蔚冰,吴立坚,等.131I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和131I-全身显像的意义[J].国际放射医学核医学杂志,2006,30(3):161.
LIN Jun,MIAO Wei-bing,WU Li-jian,et al.The value of thyroglobulin measured and 131I-whole body scan on the differentiated thyroid carcinoma with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):161.